i

DEVELOPMENT OF A CELL-BASED IMMUNOASSAY FOR CORONAVIRUS DISEASE 2019 (COVID-19) SEROLOGIC TESTING

PHRR211103-004042

DEVELOPMENT OF A CELL-BASED IMMUNOASSAY FOR CORONAVIRUS DISEASE 2019 (COVID-19) SEROLOGIC TESTING

The pandemic of coronavirus disease 2019 (COVID-19) caused severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a major global health concern. Current confirmation of COVID-19 infection is based on testing of appropriate respiratory samples using nucleic acid amplification method of reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Though this method is validated, specific and faster than virus isolation, establishment of a laboratory with appropriate biosafety clearance is warranted to conduct testing. In addition, several diagnostic inconsistencies have been reported with this method. Serological testing primarily detecting virus-specific IgM and IgG antibodies in paired serum samples (i.e. in acute and convalescent phase) has been suggested to support diagnosis of COVID-19 in cases where negative nucleic acid-based amplification tests are negative but have strong epidemiological link. Some recommend its use to aid in diagnosis of subclinical cases of COVID-19 and to determine the true extent of COVID-19 spread. In this study, we propose a low-cost, cell-based immunoassay to detect antibodies against SARS-CoV-2 (AbaCoVs) without the need for sophisticated equipment or electricity. 

 

Regime Classification Priority
2017 - 2022 Global competitiveness and innovation in health Access to essential medical products, vaccines and technologies
Start Date Duration in Months Target Completion Date Actual Completion Date
2021-02-15 12 2022-02-15 0000-00-00

Ongoing

Institution Classification Region LTO #
University of the Philippines Manila Public Higher Education Institution - State Universities and Colleges Philippines n/a
Institution Classification Region LTO #
University of the Philippines Manila Public Higher Education Institution - State Universities and Colleges Philippines
Institution Region
DOST-PCHRD NCR
Name E-Mail Institution and Institution Address
Riziel Hannah B. Aguimatang rbaguimatang@up.edu.ph University of the Philippines Manila, Malate, Manila
Name E-Mail Institution and Institution Address
Fresthel Monica M. Climacosa fmclimacosa@up.edu.ph University of the Philippines Manila, Malate, Manila
Name Expertise Affiliation
David R. McMillen Chemistry University of Toronto
Fresthel Monica M. Climacosa, MD, PhD medical microbiology, humoral immunity, reemerging infectious diseases University of the Philippines - Manila, College of Public Health
Jose Ma. M. Angeles, RMT, MPH, PhD molecular biology, serological diagnostics (schistosomiasis) University of the Philippines - Manila, College of Public Health, Department of Parasitology
Ma. Cynthia J Goh Chemistry University of Toronto
Pilarita T. Rivera MD, PhD Immunology, molecular biology, parasitic disease University of the Philippines - Manila, College of Public Health
Ruby Anne N. King, MD, PhD polymeric peptides, antibodies Biomedical Innovations Research for Translational Health Science Laboratory
Salvador Eugenio C. Caoili, MD, PhD anitbodies, epitope prediction, vaccines Biomedical Innovations Research for Translational Health Science Laboratory

Coronavirus Disease(COVID-19)

  1. To identify candidate SARS-CoV-2 antigens for immunoassay-based detection of AbaCoVs
  2. To design plasmid expression vectors containing selected SARS-CoV-2 antigens for cell-surface display on yeast cells
  3. To develop cell-surface engineered yeast that display SARS-CoV-2 proteins 
  4. To use cell-surface engineered yeast that display SARS-CoV-2 proteins in an immunoassay to detect AbaCoVs

Unspecified

Completed

  • Philippines

Non-clinical Studies

©2022 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date